



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Finer et al.

Attorney Docket No.: CYTOP009C6

Application No.: 09/724,941

Examiner: Troung, Tamthom Ngo

Filed: November 28, 2000

Group: 1624

Title: METHODS AND COMPOSITIONS
UTILIZING QUINAZOLINONES

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail to: Commissioner for Patents, Washington, DC 20231 on October 30, 2002.

Signed: 

Agnes Spence

RECEIVED

NOV 07 2002

TECH CENTER 1600/2900

AMENDMENT TRANSMITTALCommissioner for Patents
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment in the above-identified application.

The fee has been calculated as shown below.

	Claims After Amendment		Highest Previously Paid For	Present Extra	Small Entity Rate Fee	Large Entity Rate Fee
Total Claims	8	MINUS	20	0	x 9 =	x 18 = 0
Independent Claims	1	MINUS	3	0	x 42 =	x 84 = 0
Multiple Dependent Claim Present and Fee Not Previously Paid					\$140.00	\$280.00
Total					\$	\$0

- ☒ Applicant(s) hereby petition for a one month extension(s) of time to respond to the aforementioned Office Action.
- ☒ Applicant(s) believe that no (additional) Extension of Time is required; however, if it is determined that such an extension is required, Applicant(s) hereby petition that such an extension be granted and authorize the Commissioner to charge the required fees for an Extension of Time under 37 CFR 1.136 to Deposit Account No. 500388.
- ☐ Enclosed is our Check No. _____ in the amount of \$ _____ to cover the additional claim fee and/or extension of time fees.
- ☒ Please charge the required fees, or any additional fees required to facilitate filing the enclosed response, to Deposit Account No. 501339 (Order No. CYTOP009C6).

Respectfully submitted,
BEYER WEAVER & THOMAS, LLP.Lauren L. Stevens, Ph.D.
Reg. No. 36,691P.O. Box 778
Berkeley, CA 94704-0778
(650) 961-8300



THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper and the documents and/or fees referred to as attached therein are being deposited with the United States Postal Service on November 28, 2000 in an envelope as "Express Mail Post Office to Addressee" service under 37 CFR §1.10, Mailing Label Number EL711138185US, addressed to the Assistant Commissioner for Patents, Washington, DC 20231.

Sunshine Noriega
Sunshine Noriega

Attorney Docket No.: CYTOP009C6

First Named Inventor: Finer et al.

COPY
EL 711138185US

UTILITY PATENT APPLICATION TRANSMITTAL (37 CFR. § 1.53(b))
(Continuation, Divisional or Continuation-in-part application)

RECEIVED

Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

NOV 07 2002

TECH CENTER 1600/2900

Sir: This is a request for filing a patent application under 37 CFR. § 1.53(b) in the name of inventors:
Jeffrey T. Finer, Gustave Bergnes, Bainian Feng, Whitney W. Smith and John C. Chabala

For: **METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES**

This application is a ☒ Continuation ☐ Divisional ☐ Continuation-in-part

of prior Application No.: 09/699,047, from which priority under 35 U.S.C. §120 is claimed.

Application Elements:

- ☒ 75 Pages of Specification, Claims and Abstract
☒ 90 Sheets of formal Drawings
☐ Declaration and Power of Attorney
☐ Newly executed
☐ Copy from a prior application (37 CFR 1.63(d) for a continuation or divisional).
The entire disclosure of the prior application from which a copy of the declaration is herein supplied is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
☐ Deletion of inventors Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).

Accompanying Application Parts:

- ☐ Assignment and Assignment Recordation Cover Sheet (recording fee of \$40.00 enclosed)
☐ Power of Attorney

- ☐ 37 CFR 3.73(b) Statement by Assignee
☒ Information Disclosure Statement with Form PTO-1449 ☐ Copies of IDS Citations
☒ Preliminary Amendment (*New claims numbered after highest original claim in prior application.*)
☒ Return Receipt Postcard
☐ Other:

COPY

Claim For Foreign Priority

- ☐ Priority of Application No. filed on
is claimed under 35 U.S.C. § 119.
☐ The certified copy has been filed in prior application U.S. Application No.
☐ The certified copy will follow.

Extension of Time for Prior Pending Application

- ☐ A Petition for Extension of Time is being concurrently filed in the prior pending application. A copy of the Petition for Extension of Time is attached.

Amendments

- ☒ Amend the specification by inserting before the first line the sentence: "This is a
☒ Continuation ☐ Continuation-in-part ☐ Divisional
application of co-pending prior
☒ Application No. 09/699,047 filed on October 24, 2000,
☐ International Application filed on which
designated the United States,
the disclosure of which is incorporated herein by reference."
- ☒ Cancel in this application original claims 1-30, 32-52 and 57-59 of the prior application
before calculating the filing fee. (*At least one original independent claim must be retained.*)

COPY

☐ Applicant is entitled to Small Entity Status under 37 C.F.R. §1.27.

	(Col. 1) Total Claims		(Col. 2) Claims	(Col. 3) Present Extra	Rate	Additional Fee
TOTAL	0	MINUS	20	0	x 18	0.00
INDEP.	0	MINUS	3	0	x 80	0.00
[] First presentation of multiple dependent claim					\$270	
Basic Filing Fee under 37 C.F.R. §1.16(a)					\$710	0
TOTAL						0
SMALL ENTITY 50% FILING FEE REDUCTION (if applicable)						

☒ PLEASE DEFER FILING FEES AT THIS TIME


☐ The Commissioner is authorized to charge any fees beyond the amount enclosed which may be required, or to credit any overpayment, to Deposit Account No. 500388 (Order No. CYTOP009C6).

General Authorization for Petition for Extension of Time (37 CFR §1.136)

☒ Applicants hereby make and generally authorize any Petitions for Extensions of Time as may be needed for any subsequent filings. The Commissioner is also authorized to charge any extension fees under 37 CFR §1.17 as may be needed to Deposit Account No. 500388 (Order No. CYTOP009C6).

☒ Please send correspondence to the following address:

Customer Number 022434
BEYER WEAVER & THOMAS, LLP
P.O. Box 778
Berkeley, CA 94704-0778
Telephone (510) 843-6200
Fax (510) 843-6203



Date: 11/28/00

Jeffrey K. Weaver
Jeffrey K. Weaver
Registration No. 31,314



RECEIVED

NOV 07 2002

TECH CENTER 1600/2900

COPY

Docket #	CYTOP009C6	By:	JKW/lr	Date of this mailing:	November 28, 2000
Appl'n #:	NEW	Filing Date:	HEREWITH	Express Mail #	EL711138185US
Inv(s)	Finer et al.				
Title:	METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES				

The following have been received in the U.S. Patent Office on the date stamped hereon:

Item	Description	# Pgs
1.	Utility Patent Application Transmittal (Continuation)	3
2.	Patent Application Specification, Claims and Abstract (Copy)	75
3.	Informal Drawings (Copy)	90
4.	Preliminary Amendment & Appendix of Pending Claims	6
5.	Information Disclosure Statement	1
6.	PTO Form 1449	2
7.	Certificate of Express Mail	
8.	Box Patent Applications	
9.		
10.		

JC921 U.S. PTO


09/724941



11/28/00



COPY



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/724,941	11/28/2000	1614	1150	CYTOP009C6	90	5	1

CONFIRMATION NO. 9330

22434
BEYER WEAVER & THOMAS LLP
P.O. BOX 778
BERKELEY, CA 94704-0778

UPDATED FILING RECEIPT



OC000000007974947

Date Mailed: 04/29/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Gustave Bergnes, Pacifica, CA;
Whitney W. Smith, El Cerrito, CA;
John C. Chabala, Mountainside, NJ;

RECEIVED

NOV 07 2002

TECH CENTER 1600/2900

Assignment For Published Patent Application

Cytokinetics, Inc.;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CON OF 09/699,047 10/24/2000
WHICH CLAIMS BENEFIT OF 60/198,253 10/27/1999
AND CLAIMS BENEFIT OF 60/213,104 06/21/2000

Foreign Applications

If Required, Foreign Filing License Granted 03/28/2001

Projected Publication Date: Not Applicable, filed prior to November 29, 2000

Non-Publication Request: No

Early Publication Request: No

Title



Methods and compositions utilizing quinazolinones

COPY

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).